Analysts Set Expectations for Cronos Group Q1 Earnings

Key Points

• Roth Capital estimates that Cronos Group will earn $0.01 per share in Q1 2026, with a consensus estimate for the full year at a loss of ($0.03) per share.
• Wall Street Zen downgraded Cronos Group's rating from "hold" to "sell," indicating a bearish outlook.
• Cronos Group's latest earnings report showed a loss of ($0.10) EPS, missing estimates, with revenue of $33.46 million compared to expectations of $45.73 million.

Cronos Group Inc. (NASDAQ:CRON - Free Report) - Roth Capital issued their Q1 2026 earnings per share estimates for shares of Cronos Group in a research note issued to investors on Thursday, August 7th. Roth Capital analyst W. Kirk expects that the company will earn $0.01 per share for the quarter. The consensus estimate for Cronos Group's current full-year earnings is ($0.03) per share. Roth Capital also issued estimates for Cronos Group's Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.06 EPS.

Cronos Group (NASDAQ:CRON - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.08). Cronos Group had a net margin of 14.19% and a negative return on equity of 3.78%. The firm had revenue of $33.46 million for the quarter, compared to analyst estimates of $45.73 million.

Separately, Wall Street Zen cut Cronos Group from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

Cronos Group Stock Down 1.8%

Shares of Cronos Group stock traded down $0.05 during mid-day trading on Monday, reaching $2.48. 769,813 shares of the stock traded hands, compared to its average volume of 1,762,208. The business has a 50-day moving average of $2.06 and a 200 day moving average of $1.95. Cronos Group has a fifty-two week low of $1.60 and a fifty-two week high of $2.77. The stock has a market capitalization of $949.93 million, a PE ratio of 49.50 and a beta of 1.01.

Hedge Funds Weigh In On Cronos Group

A number of hedge funds have recently made changes to their positions in CRON. Bank of America Corp DE grew its position in shares of Cronos Group by 11.0% in the second quarter. Bank of America Corp DE now owns 135,180 shares of the company's stock valued at $258,000 after purchasing an additional 13,450 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Cronos Group by 15.3% in the second quarter. Raymond James Financial Inc. now owns 360,052 shares of the company's stock valued at $688,000 after purchasing an additional 47,771 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Cronos Group by 192.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 89,683 shares of the company's stock valued at $171,000 after purchasing an additional 59,013 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Cronos Group in the second quarter valued at approximately $70,000. Finally, Northwest & Ethical Investments L.P. purchased a new stake in shares of Cronos Group in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 8.71% of the company's stock.

About Cronos Group

Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.